Ginkgo Bioworks ("Ginkgo"), the organism company, today announced that it has recently completed an acquisition of the main assets of Novogy, Inc. ("Novogy"). After Forbes unveiled its annual billion-dollar startup list on Sept. 26, 2017, some anxious investors started targeting the The biotech will genetically engineer cannabinoids so that Cronos can bring cannabinoid-based products to market with reliability and scalability . Ginkgo Bioworks is a startup that turns bacteria into consumer goods, and the partnership will allow the company to apply its technology to cannabis.. From TechCrunch. )* Synlogic, Inc. (Name of Issuer) Common Stock, ��� Ginkgo Bioworks Lands $9 Million In Series A Funding To Build Out New Lab Facilities. The Organism CompanyWe���re building the backend of the bioeconomy.Biology is everywhere. Ginkgo Bioworks has inked a $122 million USD deal with Toronto's Cronos Group (TSX:CRON). BOSTON, Nov. 20, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks announced it has secured access to at least 10 million rapid antigen test kits from Access Bio, ��� U.S. Loans $1.1 Billion to Ginkgo Bioworks for Pandemic Effort By Reuters , Wire Service Content Nov. 25, 2020 By Reuters , Wire Service Content Nov. 25, 2020, at 8:08 a.m. Ginkgo Bioworks uses advanced biotechnology to grow various consumer products rather than manufacturing them, enabling fragrance, cosmetic, nutrition ��� Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Price per share is $150,19. Working with our partners and growing ecosystem, we design custom organisms that bring new products to life for countless applications. ET Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Tom Knight.The company specializes in using genetic engineering to produce bacteria with industrial applications. Ginkgo Bioworks is an analytics company that designs organisms for customers in a range of industries. BOSTON, Oct. 26, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks announced it has secured access to the SD Biosensor rapid antigen test with a goal of acquiring and distributing up to 50 million tests. Passive Investment. Ginkgo Bioworks's main competitors include LGC, Principia BioPharma, Verona Pharma and Vectura Group. SYBX stock is making solid movement after Synlogic Inc (NASDAQ:SYBX) announced an $80 million equity investment from Ginkgo Bioworks. Ginkgo Bioworks General Information Description. Featured Work:Growing Ginkgo���s Platform with Digital TechnologyJoyn BioStrain ��� It also provides probiotic bacteria to protect the body from dangerous infections and generates libraries of ��� Ginkgo Bioworks��� revenue comes from two channels. Press Release Ginkgo Bioworks CEO to Present at the 39th Annual J.P. Morgan Healthcare Conference Published: Jan. 8, 2021 at 1:44 p.m. BOSTON, Nov. 25, 2020 /PRNewswire/ -- Ginkgo Bioworks announced today that the U.S. International Development Finance Corporation (DFC) has approved a loan of up to $1.1 billion, enabling Ginkgo to expand ongoing biosecurity efforts.These include optimizing the manufacturing of COVID-19 vaccines, delivering widespread testing, and building the infrastructure needed to help ��� BOSTON, Dec. 23, 2020 /PRNewswire/ -- Today Ginkgo Bioworks, the organism company, announced the launch of its pilot program to bring COVID-19 pool ed testing to K-12 classrooms. Now Ginkgo shares on the OTC market are worth $138.6, which suggests a valuation of $4 billion. Developer of a cell programming platform intended to make biology easier to engineer. Ginko Bioworks recently closed a $9M Series A from investors including Vast Ventures, Data Collective, and Felicis Ventures (link). Tags Ginkgo Bioworks TC boston. Concentric by Ginkgo, the company's COVID-19 diagnostic testing service, will begin offering antigen testing to customers in international markets where the antigen test is authorized to ��� Cronos Group stock jumps after partnering with Boston biotech Ginkgo Bioworks in a US$122mln deal to develop cultured cannabinoids. At Ginkgo, we see the potential for biology to transform all industries. Ginkgo���s Investment is Key for Synlogic. Ginkgo Bioworks is a company that designs, engineers, develops, tests, and licenses organisms. MIRN / Mirna Therapeutics, Inc. / Ginkgo Bioworks, Inc. - SCHEDULE 13G FOR SYNLOGIC, INC. BY GINKGO BIOWORKS, INC. Its last funding in September 2019 valued the company at $4.4 billion. Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Tickers TC. It is the self-proclaimed "Organism Company" and is one of the ��� March 18, 2015. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. By accessing this page, you agree to the following Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. Compare Ginkgo Bioworks to its competitors by revenue, employee growth and other metrics at ��� 2019-06-21 sec.gov - 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. Ginkgo Bioworks has secured a total of $790 million from venture investors. It seems that the deal has excited investors as Cronos stock was up 13% on the news.. Ginkgo Bioworks Signs Deal with Cronos to ��� Ginkgo Bioworks, the organism company, today announced it is contributing its platform infrastructure and expertise to a project with Moderna, Inc. (Nasdaq: MRNA). As one of the leading biopharmaceutical companies, Synlogic Inc (SYBX) makes use of synthetic biology to genetically engineer living medicines.